XENE vs. BIIB
XENE (Xenon Pharmaceuticals Inc.) and BIIB (Biogen Inc.) are both stocks. Both are in the Healthcare sector — XENE in Biotechnology, BIIB in Drug Manufacturers - General. Over the past 10 years, XENE returned 24.15%/yr vs -1.36%/yr for BIIB. At a 0.24 correlation, their price movements are largely independent.
Performance
XENE vs. BIIB - Performance Comparison
Loading charts...
Returns By Period
In the year-to-date period, XENE achieves a 22.24% return, which is significantly higher than BIIB's 13.48% return. Over the past 10 years, XENE has outperformed BIIB with an annualized return of 24.15%, while BIIB has yielded a comparatively lower -1.36% annualized return.
XENE
- 1D
- 3.55%
- 1M
- 1.14%
- YTD
- 22.24%
- 6M
- 18.90%
- 1Y
- 70.95%
- 3Y*
- 11.05%
- 5Y*
- 24.94%
- 10Y*
- 24.15%
BIIB
- 1D
- 1.59%
- 1M
- 3.07%
- YTD
- 13.48%
- 6M
- 14.32%
- 1Y
- 57.20%
- 3Y*
- -11.13%
- 5Y*
- -11.69%
- 10Y*
- -1.36%
XENE vs. BIIB - Yearly Performance Comparison
| 2026 (YTD) | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | |
|---|---|---|---|---|---|---|---|---|---|---|
XENE Xenon Pharmaceuticals Inc. | 22.24% | 14.34% | -14.89% | 16.81% | 26.22% | 103.12% | 17.32% | 107.77% | 123.36% | -63.31% |
BIIB Biogen Inc. | 13.48% | 15.09% | -40.91% | -6.55% | 15.42% | -2.02% | -17.48% | -1.39% | -5.54% | 12.34% |
Correlation
The correlation between XENE and BIIB is 0.22, which is low. Their price movements are largely independent, making them effective diversification partners.
| Correlation | |
|---|---|
Correlation (1Y) Calculated over the trailing 1-year period | 0.22 |
Correlation (3Y) Calculated over the trailing 3-year period | 0.26 |
Correlation (5Y) Calculated over the trailing 5-year period | 0.31 |
Correlation (10Y) Calculated over the trailing 10-year period | 0.24 |
Correlation (All Time) Calculated using the full available price history since Nov 5, 2014 | 0.24 |
Fundamentals
XENE:
-$4.72
BIIB:
$12.48
XENE:
$0.00
BIIB:
$9.86B
XENE:
-$78.30M
BIIB:
$5.06B
XENE:
-$399.62M
BIIB:
$2.24B
Compare stocks, funds, or ETFs
Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.
Return for Risk
XENE vs. BIIB — Risk / Return Rank
XENE
BIIB
XENE vs. BIIB - Risk-Adjusted Trends Comparison
This table presents a comparison of risk-adjusted performance metrics for Xenon Pharmaceuticals Inc. (XENE) and Biogen Inc. (BIIB). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.
Values are calculated on a 1-year rolling basis and updated daily. Risk-adjusted metrics are more stable over longer periods — use the period switch above to explore them.
| XENE | BIIB | Difference | |
|---|---|---|---|
| Sharpe ratioReturn per unit of total volatility | -0.53 | ||
| Sortino ratioReturn per unit of downside risk | +0.63 | ||
| Omega ratioGain probability vs. loss probability | 1.35 | 1.29 | +0.06 |
| Calmar ratioReturn relative to maximum drawdown | 3.88 | 4.01 | -0.13 |
| Martin ratioReturn relative to average drawdown | 8.65 | 10.02 | -1.37 |
Loading charts...
Drawdowns
XENE vs. BIIB - Drawdown Comparison
The maximum XENE drawdown since its inception was -90.43%, roughly equal to the maximum BIIB drawdown of -89.98%. Use the drawdown chart below to compare losses from any high point for XENE and BIIB.
Loading charts...
Drawdown Indicators
| XENE | BIIB | Difference | |
|---|---|---|---|
Max DrawdownLargest peak-to-trough decline | -90.43% | -89.98% | -0.45% |
Max Drawdown (1Y)Largest decline over 1 year | -18.40% | -14.34% | -4.06% |
Max Drawdown (3Y)Largest decline over 3 years | -43.59% | -60.34% | +16.75% |
Max Drawdown (5Y)Largest decline over 5 years | -43.59% | -69.28% | +25.69% |
Max Drawdown (10Y)Largest decline over 10 years | -77.66% | -72.66% | -5.00% |
Current DrawdownCurrent decline from peak | -12.70% | -58.04% | +45.34% |
Average DrawdownAverage peak-to-trough decline | -39.42% | -36.63% | -2.79% |
Ulcer IndexDepth and duration of drawdowns from previous peaks | 8.23% | 5.73% | +2.50% |
Volatility
XENE vs. BIIB - Volatility Comparison
Xenon Pharmaceuticals Inc. (XENE) and Biogen Inc. (BIIB) have volatilities of 8.27% and 8.30%, respectively, indicating that both stocks experience similar levels of price fluctuations. This suggests that the risk associated with both stocks, as measured by volatility, is nearly the same. The chart below showcases a comparison of their rolling one-month volatility.
Loading charts...
Volatility by Period
| XENE | BIIB | Difference | |
|---|---|---|---|
Volatility (1M)Calculated over the trailing 1-month period | 8.27% | 8.30% | -0.03% |
Volatility (6M)Calculated over the trailing 6-month period | 46.47% | 24.36% | +22.11% |
Volatility (1Y)Calculated over the trailing 1-year period | 59.90% | 33.44% | +26.46% |
Volatility (5Y)Calculated over the trailing 5-year period, annualized | 67.60% | 34.27% | +33.33% |
Volatility (10Y)Calculated over the trailing 10-year period, annualized | 66.41% | 41.32% | +25.09% |
Dividends
XENE vs. BIIB - Dividend Comparison
Neither XENE nor BIIB has paid dividends to shareholders.
Financials
XENE vs. BIIB - Financials Comparison
This section allows you to compare key financial metrics between Xenon Pharmaceuticals Inc. and Biogen Inc.. You can select fields from income statements, balance sheets, and cash flow statements to easily visualize and compare the financial health of both companies.
Total Revenue: Total amount of money received from sales and other business activities
Frequently Asked Questions
XENE and BIIB have a correlation of 0.22, meaning they provide meaningful diversification benefit when combined. Depending on your allocation goals, holding both could reduce overall portfolio risk.
BIIB has higher volatility (8.30%) compared to XENE (8.27%). In terms of maximum drawdown, XENE dropped -90.43% vs BIIB's -89.98%.
BIIB currently has the higher Sharpe Ratio (1.72 vs 1.19), meaning it's delivered slightly more return per unit of risk over the trailing 12 months. However, this ranking shifts over time - use the Risk/Return Score above for a more comprehensive view that combines Sharpe, Sortino, and other measures used by quantitative funds.
Find the right allocation for XENE and BIIB
Add both to a portfolio and optimize allocations for your target — whether that's maximizing returns, minimizing drawdowns, or balancing risk across holdings.
Open Portfolio Optimizer